Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Prakriti Gaba, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. 1660-1671
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Samuel Sherratt, Peter Libby, Matthew J. Budoff, et al.
Current Atherosclerosis Reports (2022) Vol. 25, Iss. 1, pp. 1-17
Open Access | Times Cited: 77
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 5, pp. 477-495
Open Access | Times Cited: 46
Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
Daniel Rodríguez, Carl J. Lavie, Andrew Elagizi, et al.
Nutrients (2022) Vol. 14, Iss. 23, pp. 5146-5146
Open Access | Times Cited: 55
The Potential Cardiometabolic Effects of Long-Chain ω-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Jae Hyun Bae, Hyunjung Lim, Soo Lim
Advances in Nutrition (2023) Vol. 14, Iss. 4, pp. 612-628
Open Access | Times Cited: 38
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Stefan Zivkovic, Gorica Marić, Nataša Cvetinovic, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1517-1517
Open Access | Times Cited: 29
Do patients benefit from omega-3 fatty acids?
Samuel Sherratt, R. Preston Mason, Peter Libby, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 18, pp. 2884-2901
Open Access | Times Cited: 26
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur, R. Preston Mason, Philippe Gabríel Steg, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 8, pp. 1005-1014
Open Access | Times Cited: 15
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
Neila Sayah, Deepak L. Bhatt, Michael Miller, et al.
European Heart Journal (2024) Vol. 45, Iss. 13, pp. 1173-1176
Open Access | Times Cited: 11
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 1
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention
Seung‐Jun Lee, Jae Hong Joo, Sohee Park, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 5, pp. 401-410
Open Access | Times Cited: 20
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT
Mark Rabbat, Suvasini Lakshmanan, Mina M. Benjamin, et al.
European Heart Journal - Cardiovascular Imaging (2023) Vol. 24, Iss. 7, pp. 866-873
Open Access | Times Cited: 19
A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes
Samuel Sherratt, Peter Libby, Deepak L. Bhatt, et al.
Prostaglandins Leukotrienes and Essential Fatty Acids (2022) Vol. 182, pp. 102450-102450
Open Access | Times Cited: 26
Omega-3 and cardiovascular prevention – Is this still a choice?
Massimiliano Ruscica, Cesare R. Sirtori, Stefano Carugo, et al.
Pharmacological Research (2022) Vol. 182, pp. 106342-106342
Open Access | Times Cited: 23
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
Heinz Drexel, Juan Tamargo, Juan Carlos Kaski, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 6, pp. 570-582
Open Access | Times Cited: 16
Omega-3-fatty acids: Do they prevent cardiovascular disease?
R. Preston Mason, Samuel Sherratt, Robert H. Eckel
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 37, Iss. 3, pp. 101681-101681
Open Access | Times Cited: 21
Effects of omega-3, omega-6, and total dietary polyunsaturated fatty acid supplementation in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Siqi Luo, Hongmei Hou, Yongjin Wang, et al.
Food & Function (2023) Vol. 15, Iss. 3, pp. 1208-1222
Closed Access | Times Cited: 11
Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis
Nathália Mendes Machado, Maria Júlia Ribeiro de Oliveira, Karina Quesada, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 601-601
Open Access
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
Michael Miller, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 9, Iss. 2, pp. 129-137
Open Access | Times Cited: 16
VLDL receptor gene therapy for reducing atherogenic lipoproteins
Ronald M. Krauss, Jonathan T. Lu, Joseph Higgins, et al.
Molecular Metabolism (2023) Vol. 69, pp. 101685-101685
Open Access | Times Cited: 8
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease
Michael Miller
Current Opinion in Cardiology (2024)
Open Access | Times Cited: 3
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
Peter P. Tóth, M. John Chapman, Klaus G. Parhofer, et al.
American Heart Journal Plus Cardiology Research and Practice (2022) Vol. 17, pp. 100148-100148
Open Access | Times Cited: 14
Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?
Jelena Rakočević, Milan Dobrić, Milica Labudović‐Borović, et al.
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 7
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
Jessica Huston, Hannah Schaffner, Alyssa Cox, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 4, pp. 393-406
Open Access | Times Cited: 7
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, et al.
Journal of clinical lipidology (2022) Vol. 16, Iss. 4, pp. 389-402
Open Access | Times Cited: 12
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, et al.
European Heart Journal Open (2023) Vol. 3, Iss. 6
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top